Congenica Awarded £300k Innovate UK Grant
News Sep 29, 2015
The UK has pioneered the adoption of stratified medicine – the tailoring of medical treatment to the individual characteristics of each patient – an approach designed to improve the effectiveness of disease prevention and treatment. At the core of this strategy is the need to detect and classify diseases more objectively; Congenica has been awarded an Innovate UK grant to facilitate the definition of disease at the molecular level.
Life Sciences Minister George Freeman MP said:
“We are determined to make the UK the best country in Europe to innovate and to grow a business. Innovation is key to our competitiveness and productivity. This £300,000 investment will help to deliver innovative, personalised treatments that can make a real difference to NHS patients and cement the UK’s position as a world-leader in genomic science.”
Dr Tom Weaver, CEO of Cambridge-based Congenica, a spinout from the Wellcome Trust Sanger Institute, says that this grant will accelerate the development of a multi-omic approach to disease classification.
He explains; “The genome contains all of a person’s genes - the proteome, the proteins and the phenome represent the sum total of all of the characteristics or phenotypic traits. By using a multi-omic approach one can determine not only the susceptibility to a disease, but also its progression within the body”.
Creating tools that can handle and analyse this complex data and present it in a meaningful way to hospital consultants and drug developers is the ‘holy grail’ of stratified medicine.
Congenica’s platform Sapientia™ has been developed to analyse and interpret whole genome data and has been validated by Genomics England. With this grant Congenica will be able to extend its capability to include other types of -omics data.
The model developed by Genomics England, in which all stakeholders – patients, clinicians, geneticists and technologists – are involved, has proven successful in supporting the adoption of Sapientia. As a result of including end users from the outset, Sapientia is a robust diagnostic tool that has already been readily adopted by the NHS Genomic Centres in Birmingham, Great Ormond Street, Leeds, Liverpool, Manchester, Newcastle and Sheffield to assist with the detection and definition of rare diseases.
Congenica will be taking a similar stakeholder approach to this next phase, which will extend the functionality of Sapientia to enable broader and deeper clinical phenotyping of rare diseases and inherited cancers.
This project is the first of many steps to achieve this level of understanding. It aims to create a proof of concept for further investors showing that Congenica can unlock this stratified clinical data prize.
Minoryx Therapeutics spins off SEE-Tx platform into new company, Gain TherapeuticsNews
The new Swiss company will operate in Lugano and Barcelona under the scientific management of Minoryx co-founder Dr Xavier Barril.READ MORE
Evolution Threatens Efficient Bioproduction Scale-UpNews
The transition towards sustainable biobased chemical production is important for green growth, but productivity and yield of engineered cells frequently decrease in large industry-scale fermentation. According to a new study, the role of evolution has been underestimated in limiting bioprocesses.